CUREVAC NV (CVAC) Stock Fundamental Analysis
USA - NASDAQ:CVAC - NL0015436031 - Common Stock
5.28 USD
+0.05 (+0.96%)
5.28 USD
0 (0%)
Overall CVAC gets a fundamental rating of 6 out of 10. We evaluated CVAC against 531 industry peers in the Biotechnology industry. While CVAC has a great health rating, its profitability is only average at the moment. CVAC has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year CVAC was profitable.
In the past year CVAC had a positive cash flow from operations.
In the past 5 years CVAC reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: CVAC reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 28.11%, CVAC belongs to the top of the industry, outperforming 97.93% of the companies in the same industry.
CVAC's Return On Equity of 33.02% is amongst the best of the industry. CVAC outperforms 97.74% of its industry peers.
CVAC has a Return On Invested Capital of 28.35%. This is amongst the best in the industry. CVAC outperforms 98.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROIC | 28.35% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CVAC has a Profit Margin of 37.93%. This is amongst the best in the industry. CVAC outperforms 96.99% of its industry peers.
CVAC's Operating Margin of 40.58% is amongst the best of the industry. CVAC outperforms 98.49% of its industry peers.
The Gross Margin of CVAC (94.81%) is better than 94.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CVAC is creating value.
CVAC has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for CVAC has been increased compared to 5 years ago.
Compared to 1 year ago, CVAC has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 9.44 indicates that CVAC is not in any danger for bankruptcy at the moment.
CVAC's Altman-Z score of 9.44 is amongst the best of the industry. CVAC outperforms 83.62% of its industry peers.
CVAC has a debt to FCF ratio of 0.18. This is a very positive value and a sign of high solvency as it would only need 0.18 years to pay back of all of its debts.
CVAC's Debt to FCF ratio of 0.18 is amongst the best of the industry. CVAC outperforms 95.67% of its industry peers.
CVAC has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
CVAC's Debt to Equity ratio of 0.05 is on the low side compared to the rest of the industry. CVAC is outperformed by 60.83% of its industry peers.
Even though the debt/equity ratio score it not favorable for CVAC, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Altman-Z | 9.44 |
ROIC/WACC3.91
WACC7.25%
2.3 Liquidity
CVAC has a Current Ratio of 6.17. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CVAC (6.17) is better than 65.16% of its industry peers.
CVAC has a Quick Ratio of 6.16. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.16, CVAC is doing good in the industry, outperforming 66.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 |
3. Growth
3.1 Past
CVAC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 170.16%, which is quite impressive.
Looking at the last year, CVAC shows a very strong growth in Revenue. The Revenue has grown by 675.15%.
CVAC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.42% yearly.
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
3.2 Future
The Earnings Per Share is expected to decrease by -22.50% on average over the next years. This is quite bad
CVAC is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -10.88% yearly.
EPS Next Y-170.56%
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-86.75%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.85%
Revenue Next 5Y-10.88%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 5.23, which indicates a rather cheap valuation of CVAC.
Based on the Price/Earnings ratio, CVAC is valued cheaply inside the industry as 98.87% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.35, CVAC is valued rather cheaply.
CVAC is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.23 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CVAC is valued cheaply inside the industry as 99.06% of the companies are valued more expensively.
CVAC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CVAC is cheaper than 99.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.24 | ||
| EV/EBITDA | 2.91 |
4.3 Compensation for Growth
The decent profitability rating of CVAC may justify a higher PE ratio.
CVAC's earnings are expected to decrease with -28.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
5. Dividend
5.1 Amount
CVAC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.28
+0.05 (+0.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners6.53%
Inst Owner Change-9.06%
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap1.19B
Revenue(TTM)510.51M
Net Income(TTM)193.64M
Analysts72.31
Price Target4.92 (-6.82%)
Short Float %0.97%
Short Ratio2.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.18%
Min EPS beat(2)-39.67%
Max EPS beat(2)-18.68%
EPS beat(4)2
Avg EPS beat(4)34.62%
Min EPS beat(4)-39.67%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)-1.81%
EPS beat(12)5
Avg EPS beat(12)-8.17%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-91.68%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)-86.88%
Revenue beat(4)2
Avg Revenue beat(4)75.38%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)366.65%
Revenue beat(8)4
Avg Revenue beat(8)53.09%
Revenue beat(12)4
Avg Revenue beat(12)21.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.9%
EPS NQ rev (1m)-275%
EPS NQ rev (3m)-275%
EPS NY rev (1m)-7.12%
EPS NY rev (3m)-7.12%
Revenue NQ rev (1m)150.78%
Revenue NQ rev (3m)220.62%
Revenue NY rev (1m)0.35%
Revenue NY rev (3m)-13.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.23 | ||
| Fwd PE | N/A | ||
| P/S | 2.01 | ||
| P/FCF | 5.24 | ||
| P/OCF | 5.03 | ||
| P/B | 1.75 | ||
| P/tB | 1.83 | ||
| EV/EBITDA | 2.91 |
EPS(TTM)1.01
EY19.13%
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)1.01
FCFY19.09%
OCF(TTM)1.05
OCFY19.86%
SpS2.62
BVpS3.01
TBVpS2.88
PEG (NY)N/A
PEG (5Y)N/A
Graham Number8.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROCE | 33.37% | ||
| ROIC | 28.35% | ||
| ROICexc | 78.22% | ||
| ROICexgc | 88.03% | ||
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% | ||
| FCFM | 38.42% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Debt/EBITDA | 0.14 | ||
| Cap/Depr | 44.58% | ||
| Cap/Sales | 1.55% | ||
| Interest Coverage | 91.31 | ||
| Cash Conversion | 90.71% | ||
| Profit Quality | 101.3% | ||
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 | ||
| Altman-Z | 9.44 |
F-Score9
WACC7.25%
ROIC/WACC3.91
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y-170.56%
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
Revenue Next Year-86.75%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.85%
Revenue Next 5Y-10.88%
EBIT growth 1Y171.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-152.22%
EBIT Next 3Y-32.99%
EBIT Next 5Y10.78%
FCF growth 1Y160.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y182.06%
OCF growth 3YN/A
OCF growth 5YN/A
CUREVAC NV / CVAC FAQ
Can you provide the ChartMill fundamental rating for CUREVAC NV?
ChartMill assigns a fundamental rating of 6 / 10 to CVAC.
What is the valuation status of CUREVAC NV (CVAC) stock?
ChartMill assigns a valuation rating of 5 / 10 to CUREVAC NV (CVAC). This can be considered as Fairly Valued.
Can you provide the profitability details for CUREVAC NV?
CUREVAC NV (CVAC) has a profitability rating of 6 / 10.
What are the PE and PB ratios of CUREVAC NV (CVAC) stock?
The Price/Earnings (PE) ratio for CUREVAC NV (CVAC) is 5.23 and the Price/Book (PB) ratio is 1.75.
Can you provide the expected EPS growth for CVAC stock?
The Earnings per Share (EPS) of CUREVAC NV (CVAC) is expected to decline by -170.56% in the next year.